HOOK - HOOKIPA Pharma Inc.

1.14
-0.004   -0.351%

Share volume: 6,469
Last Updated: 04-22-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$1.14
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
-1.56%
1 Month
5.56%
3 Months
14.30%
6 Months
27.73%
1 Year
25.27%
2 Year
25.27%
Key data
Stock price
$1.14
P/E Ratio 
N/A
DAY RANGE
$1.13 - $1.16
EPS 
N/A
52 WEEK RANGE
$0.84 - $1.16
52 WEEK CHANGE
$25.27
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$2,702
AVERAGE 30 VOLUME 
$9,415
Company detail
CEO: Jörn Aldag
Region: US
Website: www.hookipapharma.com
Employees: 160
IPO year: 2025
Issue type:
Market: OTCM
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

HOOKIPA Pharma Inc. develops immunotherapeutics targeting infectious diseases and cancers. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers.

Recent news